newsfilter
← Latest News
GlobeNewswire·

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

Telix's first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals.Findings